We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Prasugrel Re-load Strategies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01201772
Recruitment Status : Completed
First Posted : September 15, 2010
Results First Posted : January 18, 2013
Last Update Posted : January 18, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
A higher degree of platelet inhibition remains the goal of peri-interventional and long-term anti-thrombotic therapy in patients with coronary artery disease. In clinical practice, patients undergoing percutaneous coronary intervention with stent implantation who are already on clopidogrel therapy get re-loaded with clopidogrel. This is based on prior observations showing that higher inhibition of platelet aggregation may be achieved by giving a loading dose of clopidogrel in patients with coronary artery disease while on chronic clopidogrel therapy. However, to date it is unknown if greater inhibition of platelet aggregation can be achieved by adding a prasugrel loading dose in patients on chronic prasugrel therapy. Therefore, understanding the pharmacodynamic implications of a prasugrel re-load strategy in patients on already on chronic prasugrel therapy will be useful.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Drug: Prasugrel Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 65 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Impact of Prasugrel Re-load on Platelet Aggregation in Patients on Chronic Prasugrel Therapy
Study Start Date : August 2010
Primary Completion Date : May 2011
Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Prasugrel
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Prasugrel 60mg
Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
Drug: Prasugrel
Prasugrel 10mg, 30mg, or 60mg
Active Comparator: Prasugrel 30mg
Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
Drug: Prasugrel
Prasugrel 10mg, 30mg, or 60mg
No Intervention: Prasugrel 10mg
Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel

Outcome Measures

Primary Outcome Measures :
  1. PRI Levels at 4 Hours [ Time Frame: 4 hours after treatment ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with angiographically documented coronary artery disease.
  2. Age between 18 to 74 years
  3. On treatment with prasugrel 10mg/daily for at least 14 days.

Exclusion Criteria:

  1. Blood dyscrasias or bleeding diathesis
  2. Antiplatelet treatment with clopidogrel or ticlopidine
  3. Recent antiplatelet treatment (< 14 days) with a glycoprotein IIb/IIIa antagonist
  4. Platelet count <100x106/µL
  5. Active bleeding or hemodynamic instability.
  6. Unstable angina, acute or recent (<14 days) myocardial infarction.
  7. Serum creatinine >2 mg/dL
  8. Baseline ALT >2.5 times the upper limit of normal
  9. Oral anticoagulation with a coumarin derivative
  10. History of stroke, TIA or intracranial bleeding
  11. Weight <60kg
  12. Pregnant females
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01201772

United States, Florida
University of Florida
Jacksonville, Florida, United States, 32209
Sponsors and Collaborators
University of Florida
Principal Investigator: Dominick Angiolillo, MD, PhD University of Florida
More Information

Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT01201772     History of Changes
Other Study ID Numbers: UFJ 2010-49
First Posted: September 15, 2010    Key Record Dates
Results First Posted: January 18, 2013
Last Update Posted: January 18, 2013
Last Verified: December 2011

Keywords provided by University of Florida:
coronary artery disease
percutaneous coronary revascularization
prasugrel therapy

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Prasugrel Hydrochloride
Platelet Aggregation Inhibitors